Related Experiment Videos
Tumor cell surface determinants in host immunity against metastases
1Department of Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Seminars in Cancer Biology
|June 1, 1991
Summary
Harnessing the body's natural defenses to treat cancer is a key goal. Understanding major histocompatibility antigens (MHC) and tumor antigens can improve cancer immunogenicity manipulation.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Cancer treatment aims to leverage natural host defense mechanisms.
- Major histocompatibility antigens (MHC) and their interaction with peptide antigens are crucial for T cell immunity.
- Tumor rejection antigens are increasingly understood, offering new avenues for cancer therapy.
Purpose of the Study:
- To explore the potential of manipulating tumor immunogenicity by expanding the understanding of MHC and tumor rejection antigens.
- To investigate the role of MHC class I downregulation in cancer immune evasion.
Main Methods:
- Reviewing existing research on MHC structure and function.
- Integrating data on T cell immunity and tumor rejection antigens.
- Describing experimental systems involving MHC class I downregulation in tumors.
Main Results:
- Downregulation of MHC class I is observed in both murine and human tumors.
- Manipulation of experimental systems demonstrates potential therapeutic strategies.
Conclusions:
- A deeper understanding of MHC and tumor antigens can enhance cancer treatment strategies.
- Targeting MHC class I downregulation may be a viable approach to improve anti-tumor immunity.